AstraZeneca shares fall on report of potential China probe fallout
AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior executives at its China unit could be implicated in the largest insurance fraud case in the country's pharma sector in years.
AstraZeneca's shares have fallen more than 8% on speculation about an anti-corruption probe in China, its second-largest ...
AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially ...
Seeking Alpha on MSN13h
AstraZeneca falls as fraud investigation reportedly expands in China (update)An insurance fraud investigation linked to AstraZeneca (AZN) expands in China involving dozens of senior executives. Read ...
AstraZeneca said on Tuesday that it does not comment on speculative media reports, in response to a sharp drop in its share ...
Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...
China, for instance, does have the scope and opportunity to engage in short-term fiscal support of its local government as ...
AstraZeneca suffered a £14bn share price hit on Tuesday after Chinese media reported more details about an investigation into ...
The decision comes after media reports said it had indefinitely suspended plans to build two battery plants in Germany. The ...
China should stop reasoning based on manufacturing costs, according to Wang Cheng, an executive at a pharmaceutical firm.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback